期刊文献+

罗格列酮对哮喘大鼠引哮喘发作潜伏期的影响 被引量:1

Effect of rosiglitazone on the latent period of asthma in rats with asthma
原文传递
导出
摘要 目的观察过氧化物酶体增殖物活化受体γ(PPARγ)配体罗格列酮(RSG)对支气管哮喘(哮喘)大鼠气道哮喘发作潜伏期的影响。方法 SD大鼠75只,分为正常对照组(A组)、哮喘组(B组)、RSG治疗组(C组),每组25只。制备各组大鼠体外去上皮气管环,比较在0.05mmol·L-1、0.5mmol·L-1、5.0mmol·L-1浓度梯度乙酰胆碱(ACh)激发下,各组大鼠体外气管环收缩张力大小。观察三种浓度0.01mmol·L-1、0.1mmol·L-1、1.0mmol·L-1RSG对A、B两组大鼠体外气管环的ACh量效曲线的影响,比较各组大鼠引喘潜伏期差异。结果三组大鼠引喘潜伏期分别为A组(121.50±17.44)s,B组(61.50±17.68)s,C组(94.40±21.17)s,差异有统计学意义(P<0.05,n=20)。三组大鼠气管环对三种浓度ACh的反应率,B>C>A组,差异有统计学意义(P<0.05,n=20)。RSG可引起A、B两组大鼠体外气管环ACh量效曲线右移。结论 RSG可延长哮喘发作潜伏期,降低气道收缩张力,可能具有减轻气道高反应性、减少哮喘发作的作用。 Objective To observe the function of peroxisome proliferator activated receptor(PPARγ) and rosiglitazone (RSG) on the experimental rats bronchial asthma (known as asthma ) airway hyperresp-onsiveness. Methods 75 male SD rats were randomly divided into 3 groups, control group ( group A), the asthma group( group B), RSG treatment group( group C) , each group contains 25 experimental rats. The latent period of asthma in all groups were measured. Isolated tracheal rings of rats, without epithelium, were prepared. The contraction tension strength which were induced by the concentration gradient of ACh (0.05 mmol·L^-1 , 0.5 mmol·L^-1 , 5.0 mmol·L^-1 ) on the isolated tracheal rings in three groups were compared. The effect on the ACh dose-response curves of isolated tracheal rings in rats from group A and group B caused by three different concentration gradient of RSG, 0.01 mmol·L^-1 , 0.1 mmol·L^-1 and 1.0 mmol·L^-1 were observed. Results 3 groups' incubation period of asthma were 121.50 ± 17.44 s ( group A), 61.50 ± 17.68 s (group B) , 94.40 ±21.17 s (group C) , and there were significant differences (P 〈0.05, n =20). The response rate of tracheal rings in rats from three groups , B 〉 C 〉 A, and there were significant differences (P 〈 0. 05, n = 20). With the RSG, ACh dose-response curves of isolated tracheal shift significantly to the right side in rats from group A and group B. Conclusions RSG can extend the incubation period of asthma, lower the airway contraction. Reduce the airway hyperresponsiveness and asthma attack.
出处 《中华肺部疾病杂志(电子版)》 CAS 2013年第3期43-46,共4页 Chinese Journal of Lung Diseases(Electronic Edition)
基金 四川省卫生厅科研课题(070207)
关键词 罗格列酮 支气管哮喘 气道 过氧化物酶增殖物活化受体γ Rosiglitazone Bronchial asthma Airway Peroxisome proliferater activated receptor γ
  • 相关文献

参考文献16

  • 1Stamenovic D. Cytoskeletal mechanics in airway smooth muscle cells [J]. Re-spir Physiolo Neurohiol , 2008,163(1-3): 25-32.
  • 2Lauzon AM, Leguillette R. Molecular mechanics of smooth muscle contractile proteins in airway hyperresponsiveness and asthma [ J] . Proc Am Thorac Soc, 2008, 5 (1 ) : 4046.
  • 3Gil FR, Lauzon AM. Smooth muscle molecular mechanics in airway hyper-responsiveness and asthma [ J ]. Can J Physiol Pharmacol, 2007, 85 (1): 133-140.
  • 4陈健,戴爱国,胡瑞成,朱黎明.支气管哮喘豚鼠BALF炎症细胞中PPARγ、Nrf2和γ-GCS-h表达的变化[J].中国病理生理杂志,2010,26(4):760-765. 被引量:9
  • 5Loyens M, Honda K, Woerly G, et al. Peroxisome proliferator activated receptors 0. and-y down regulate allergic inflammation and eosinophil activation[J]. J Exp Med, 2003, 198 (3) : 411421.
  • 6Delayre-Orthez C, Becker J, Auwer J, et al. Suppression of allergen?induced airway inflammation and immune response by the peroxisome proliferatoractivated receptor-alpha agonist fenofibrate [J]. EurJ Pharmacol, 2008, 581(1-2): 177-184.
  • 7鲍志坚,向旭东,邓军卫,闫淑珍,陈平.过氧化物酶体增殖活化受体γ对支气管哮喘豚鼠气道炎症的影响[J].中华结核和呼吸杂志,2004,27(3):169-173. 被引量:8
  • 8Trifilieff A, Bench A, Hanley M, et al. PPAR-alpha and-gamma but not-delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF -kappall-independent effect [J]. Br J Pharmacol, 2003, 139 (1 ) : 163-171.
  • 9Mueller C, Weaver V, Vanden Heuvel JP, et al. Peroxisome proliferator?activated receptor gamma ligands attenuate immunological symptoms of experimental allergic asthma [J] . Arch Biochem Biophys, 2003, 418(2) : 186-196.
  • 10李胜梅(综述),陈卫平,沈朝斌(审校).过氧化物酶增殖活化受体γ与哮喘相关性研究进展[J].国际儿科学杂志,2010,37(1):23-25. 被引量:3

二级参考文献43

  • 1林书典,戴爱国,徐平.慢性阻塞性肺疾病患者γ谷氨酰半胱氨酸合成酶活性及表达的变化[J].中华结核和呼吸杂志,2005,28(2):97-101. 被引量:32
  • 2朱运福,戴爱国,胡瑞成.支气管哮喘豚鼠肺组织中Nrf2对γ-GCS的作用[J].中国应用生理学杂志,2006,22(4):492-496. 被引量:11
  • 3Abdelrahman M,Sivarajah A.Thiemermann C.Beneticial effects of PPAR gamma ligands in ischemia-reperfusion injury inflammation and shock. Cardiovasc Res, 2005,65(4) :772-781.
  • 4Denning GM, Stoll LL. Peroxisome proliferator-activated receptors : potential therapeutic targets in lung disease. Pedlary Pulmonol, 2006,41 ( 1 ) : 23-34.
  • 5Boyault S.Bianchi A.Moulin D,etal 15-Deoxy-Delta( 12, 14)-prostaglandin J (2) Inhibits IL-1BETA-induced IKK enzymatic activity and lkappaBaIpha degradation in rat chondrocytes through a PPARgamma-independent pathway. FEBS Lett, 2004,572 ( 1-3 ) : 33- 40.
  • 6Henke BR.. Peroxisome proliferator-activated receptor gamma(PPAR ganun a) ligands and their therapeutic utility. Prog Med Chem, 2004,42 : 1-53.
  • 7Knnuff C, Auwerx J. Perxisome prdiferator-activated receptor-gamma calls for activation in moderation: lesions from genetics and pharmacology. Endocr Rev, 2004,25 (6) : 899-9 l 8.
  • 8Acton JJ 3rd, Black RM, Jones AB, et al. Benzoyl 2-methyl indoles as selective PPARganna modulators. Bioorg Med Chem Lett, 2005, 15 ( 2 ) : 357-362.
  • 9Minoura H, Takeshita S, Ita M, et al. Pharmacoligical characteristics of a novel nonthinzolidinedione insulin sensitizer, FK614. Eur J Pharmacol. 2004,494(2-3) :273-281.
  • 10Alarcon de la Latstra C, Sanchez-Fidalgo S, Villgas I. New pharmacolgical perspectives and therapeutic potential of PPAR-gamma agonists. Curr Pharm Des,2004, 10(28) :3505-3524.

共引文献17

同被引文献5

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部